The incidence of anaphylaxis following intravenous phytonadione (vitamin K1)

A 5-year retrospective review

Douglas L. Riegert-Johnson, Gerald W. Volcheck

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Background: Phytonadione (vitamin K1) administered intravenously (IV) has been associated with anaphylaxis, although the incidence is not known. The anaphylaxis is thought to be attributable to the solubilizing vehicle, polyethoxylated castor oil (Cremophor EL, BASF AG, Ludwingshafen, Germany). Objective: To estimate the incidence of anaphylaxis after IV administration of phytonadione. Methods: A retrospective review of anaphylaxis after IV phytonadione over a 58-month period at a large academic center was performed. During the period of the study a protocol for the administration of IV phytonadione was in place. A review of computerized records and survey of staff identified cases of anaphylaxis meeting predefined inclusion criteria. In addition, a literature review was performed for articles concerning anaphylaxis after IV phytonadione. Results: Over the 58 months of the study, a total of 6,572 doses of IV phytonadione were administered. Two cases of anaphylaxis after IV phytonadione were identified. The incidence of anaphylaxis was 3 per 10,000 doses with 95% confidence intervals of 0.04 to 11 per 10,000 doses. The literature review identified 14 cases meeting inclusion criteria with no reviews of the literature or estimates of incidence. Conclusions: The incidence of anaphylaxis after IV phytonadione is overall comparable or slightly less than other drugs known to cause anaphylaxis. We do not recommend routine pretreatment with antihistamines or corticosteroids before administration of phytonadione.

Original languageEnglish (US)
Pages (from-to)400-406
Number of pages7
JournalAnnals of Allergy, Asthma and Immunology
Volume89
Issue number4
StatePublished - Oct 1 2002

Fingerprint

Vitamin K 1
Anaphylaxis
Incidence
Histamine Antagonists
Germany
Adrenal Cortex Hormones
Confidence Intervals

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

The incidence of anaphylaxis following intravenous phytonadione (vitamin K1) : A 5-year retrospective review. / Riegert-Johnson, Douglas L.; Volcheck, Gerald W.

In: Annals of Allergy, Asthma and Immunology, Vol. 89, No. 4, 01.10.2002, p. 400-406.

Research output: Contribution to journalArticle

@article{492ca1343ca147cbb628e971cd3c412f,
title = "The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): A 5-year retrospective review",
abstract = "Background: Phytonadione (vitamin K1) administered intravenously (IV) has been associated with anaphylaxis, although the incidence is not known. The anaphylaxis is thought to be attributable to the solubilizing vehicle, polyethoxylated castor oil (Cremophor EL, BASF AG, Ludwingshafen, Germany). Objective: To estimate the incidence of anaphylaxis after IV administration of phytonadione. Methods: A retrospective review of anaphylaxis after IV phytonadione over a 58-month period at a large academic center was performed. During the period of the study a protocol for the administration of IV phytonadione was in place. A review of computerized records and survey of staff identified cases of anaphylaxis meeting predefined inclusion criteria. In addition, a literature review was performed for articles concerning anaphylaxis after IV phytonadione. Results: Over the 58 months of the study, a total of 6,572 doses of IV phytonadione were administered. Two cases of anaphylaxis after IV phytonadione were identified. The incidence of anaphylaxis was 3 per 10,000 doses with 95{\%} confidence intervals of 0.04 to 11 per 10,000 doses. The literature review identified 14 cases meeting inclusion criteria with no reviews of the literature or estimates of incidence. Conclusions: The incidence of anaphylaxis after IV phytonadione is overall comparable or slightly less than other drugs known to cause anaphylaxis. We do not recommend routine pretreatment with antihistamines or corticosteroids before administration of phytonadione.",
author = "Riegert-Johnson, {Douglas L.} and Volcheck, {Gerald W.}",
year = "2002",
month = "10",
day = "1",
language = "English (US)",
volume = "89",
pages = "400--406",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "4",

}

TY - JOUR

T1 - The incidence of anaphylaxis following intravenous phytonadione (vitamin K1)

T2 - A 5-year retrospective review

AU - Riegert-Johnson, Douglas L.

AU - Volcheck, Gerald W.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Background: Phytonadione (vitamin K1) administered intravenously (IV) has been associated with anaphylaxis, although the incidence is not known. The anaphylaxis is thought to be attributable to the solubilizing vehicle, polyethoxylated castor oil (Cremophor EL, BASF AG, Ludwingshafen, Germany). Objective: To estimate the incidence of anaphylaxis after IV administration of phytonadione. Methods: A retrospective review of anaphylaxis after IV phytonadione over a 58-month period at a large academic center was performed. During the period of the study a protocol for the administration of IV phytonadione was in place. A review of computerized records and survey of staff identified cases of anaphylaxis meeting predefined inclusion criteria. In addition, a literature review was performed for articles concerning anaphylaxis after IV phytonadione. Results: Over the 58 months of the study, a total of 6,572 doses of IV phytonadione were administered. Two cases of anaphylaxis after IV phytonadione were identified. The incidence of anaphylaxis was 3 per 10,000 doses with 95% confidence intervals of 0.04 to 11 per 10,000 doses. The literature review identified 14 cases meeting inclusion criteria with no reviews of the literature or estimates of incidence. Conclusions: The incidence of anaphylaxis after IV phytonadione is overall comparable or slightly less than other drugs known to cause anaphylaxis. We do not recommend routine pretreatment with antihistamines or corticosteroids before administration of phytonadione.

AB - Background: Phytonadione (vitamin K1) administered intravenously (IV) has been associated with anaphylaxis, although the incidence is not known. The anaphylaxis is thought to be attributable to the solubilizing vehicle, polyethoxylated castor oil (Cremophor EL, BASF AG, Ludwingshafen, Germany). Objective: To estimate the incidence of anaphylaxis after IV administration of phytonadione. Methods: A retrospective review of anaphylaxis after IV phytonadione over a 58-month period at a large academic center was performed. During the period of the study a protocol for the administration of IV phytonadione was in place. A review of computerized records and survey of staff identified cases of anaphylaxis meeting predefined inclusion criteria. In addition, a literature review was performed for articles concerning anaphylaxis after IV phytonadione. Results: Over the 58 months of the study, a total of 6,572 doses of IV phytonadione were administered. Two cases of anaphylaxis after IV phytonadione were identified. The incidence of anaphylaxis was 3 per 10,000 doses with 95% confidence intervals of 0.04 to 11 per 10,000 doses. The literature review identified 14 cases meeting inclusion criteria with no reviews of the literature or estimates of incidence. Conclusions: The incidence of anaphylaxis after IV phytonadione is overall comparable or slightly less than other drugs known to cause anaphylaxis. We do not recommend routine pretreatment with antihistamines or corticosteroids before administration of phytonadione.

UR - http://www.scopus.com/inward/record.url?scp=0036824455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036824455&partnerID=8YFLogxK

M3 - Article

VL - 89

SP - 400

EP - 406

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 4

ER -